RAdx6 Profile

Serum

3 mL

1 mL (Note: This volume does not allow for repeat testing.)

Red-top tube or gel-barrier tube

The RAdx6 is a novel comprehensive diagnostic and prognostic panel for rheumatoid arthritis available exclusively at RDL. It combines 4 novel markers (14-3-3n, anti-CEP-1 anti-Sa and anti-CarP) with 2 traditional marker anti-CCP and RF) to not only enhance the diagnosis of RA in early or established disease, but also to help predict disease severity. If 14-3-3n and/or anti-Sa positivity is present, the disappearance or decrease of these antibodies with treatment is associated with less radiographic progression. In pre-clinical RA, positivity of anti-CEP-1 along with anti-CCP antibodies significantly raises the risk of imminently developing clinical RA.

Anti-CarP may predict the development of RA independently of Anti-CCP and may be present years before the onset of symptoms in RA. Anti-CarP may confer a 10% incremental benefit in identify early RA and is associated with more active disease and higher risk of developing joint erosions.

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Enzyme-linked immunosorbent assay (ELISA)